Background. The active components of Cannabis sativa L., Cannabinoids, traditionally used
in the field of cancer for alleviation of pain, nausea, wasting and improvement of well-being …

Abstract The cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor agonist Δ9-
tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in …

Simple Summary Glioblastoma (GBM) is the most frequent primary brain tumor entity with
poor prognosis and resistance to current standard therapies. Cannabinoids, such as …

Abstract Objective Cannabinoids, including delta-8-and delta-9-tetrahydrocannabinol (THC)
have a palliative care impact and may therefore be beneficial against cancer. The aim of this …

Deregulation of cell survival pathways and resistance to apoptosis are widely accepted to be
fundamental aspects of tumorigenesis. As in many tumours, the aberrant growth and survival …

Drugs that target the endocannabinoid system are of interest as pharmacological options to
combat cancer and to improve the life quality of cancer patients. From this perspective …

We recently reported that Δ9-tetrahydrocannabinol (Δ9-THC) has the ability to stimulate the
proliferation of human breast carcinoma MCF-7 cells. However, the mechanism of action …

Cannabinoids, the active components of Cannabis sativa L., act in the body by mimicking
endogenous substances—the endocannabinoids—that activate specific cell surface …

Abstract Δ 9-Tetrahydrocannabinol (THC) is the primary cannabinoid of marijuana and has
been shown to either potentiate or inhibit tumor growth, depending on the type of cancer and …

Cancer is a complex family of diseases affecting millions of people worldwide. Gliomas are
primary brain tumors that account for~ 80% of all malignant brain tumors. Glioblastoma …